I was suprised when I saw that as well. I can't imagine they paid too much for it since the company was in bankrupcy. I wonder if Merck KG just took a feeler on the program since its not costing them much as an avenue for a potential "BioBetter" of Copaxone?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.